{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"96.5","upperLimit":"97.68","value":"97.07"},{"groupId":"OG001","lowerLimit":"86.92","upperLimit":"94.02","value":"90.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4614"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"description":"Overall survival by Day 29 MRD status (negative vs positive), Overall survival defined as time from study entry to death or date of last contact for patients who are alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) \\< 0.1% OR MRD \\>= 0.1% and \\< 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD \\>= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study.\n\ncytarabine: Given IV or SC\n\ndexamethasone: Given IV or PO\n\npegaspargase: Given IM\n\nmethotrexate: Given IM or IT\n\nvincristine sulfate: Given IV","id":"OG000","title":"Induction Therapy, MRD Negative"},{"description":"All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) \\< 0.1% OR MRD \\>= 0.1% and \\< 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD \\>= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study.\n\ncytarabine: Given IV or SC\n\ndexamethasone: Given IV or PO\n\npegaspargase: Given IM\n\nmethotrexate: Given IM or IT\n\nvincristine sulfate: Given IV","id":"OG001","title":"Induction Therapy, MRD Positive"}],"paramType":"NUMBER","populationDescription":"4981 eligible evaluable patients enrolled on AALL0331 had MRD data at Day 29.","reportingStatus":"POSTED","timeFrame":"Overall Survival Probability of 6 years","title":"Overall Survival Probability (OS) According to Induction Day 29 MRD Status","type":"SECONDARY","unitOfMeasure":"percent probability"}